NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global North America Precision Medicine Market Size, Share and Trends Analysis

Global Precision Medicine market valued at $70.0B in 2023, projected to reach $207.0B by 2032 at 12.8% CAGR.

Revenue, 2023

$70.0B

Forecast, 2032

$207.0B

CAGR, 2024-2032

12.8%

Report Coverage

North America

Code: north-america-precision-medicine-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global precision medicine market was valued at $70.0 billion in 2023 and is projected to reach $207.0 billion by 2032, growing at a 12.8% CAGR. North America leads with 45% global share, driven by genomic advances, AI integration, and rising oncology demand. Key players include Illumina, Roche, and Novartis.

02

Key Highlights

1

North America commands 45% global market share driven by advanced healthcare infrastructure and leading biotech firms.

2

Oncology dominates with 40% application share fueled by CAR-T and targeted therapy breakthroughs.

3

Genomics holds 35% technology share as sequencing costs decline and AI integration accelerates.

03

Market Overview

Market Context

Precision medicine leverages genomic, proteomic, and metabolomic data to deliver targeted therapies. North America leads global adoption, supported by robust R&D funding, FDA regulatory frameworks, and major biotech hubs. Oncology dominates applications.

Precision medicine leverages genomic and molecular data to deliver targeted therapies. North America dominates with 45% global share, supported by robust R&D funding and FDA regulatory frameworks. Oncology leads application segments while genomics leads technology adoption.

Market Stage

High growth

Adoption Level

Growing

Key Trends

AI and machine learning integration in genomic diagnosticsDeclining DNA sequencing costs accelerating clinical adoptionExpansion of CAR-T and cell gene therapiesGrowing companion diagnostics demand in oncology
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 12.8%

Base Year (2023)

$70.0B

Forecast (2032)

$207.0B

CAGR (2024-2032)

12.8%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$70.00B
2024$78.96B
2025$89.07B
2026$100.47B
2027$113.33B
2028$127.83B
2029$144.20B
2030$162.65B
2031$183.47B
2032$206.96B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

Sustained double-digit growth is driven by declining sequencing costs, AI-powered diagnostics, and expanding companion diagnostics adoption. Oncology and rare diseases remain primary growth vectors through 2032.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America45.0%13.2%United States
Europe30.0%11.5%Germany
Asia Pacific25.0%16.8%China

North America

#1
Share: 45.0%CAGR: 13.2%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 11.5%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Declining genomic sequencing costs enabling broader clinical adoption
  • Rising cancer and chronic disease prevalence demanding targeted therapies
  • AI and big data analytics accelerating drug discovery and diagnostics
06

Market Segmentation

By Technology
Market share distribution across 4 segments
By Technology — market share by segment, in percent.
SegmentShare
GenomicsLargest segment driven by next-generation sequencing and whole-genome analysis applications.35.0%
BioinformaticsCritical for data interpretation and AI-driven biomarker discovery in clinical settings.25.0%
Gene TherapyRapidly growing with approved CAR-T therapies and expanding rare disease pipeline.20.0%
ImmunotherapyCheckpoint inhibitors and personalized cancer vaccines driving significant clinical adoption.20.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 5 segments
By Application — market share by segment, in percent.
SegmentShare
OncologyLargest application segment fueled by targeted therapies and companion diagnostics.40.0%
CardiovascularPharmacogenomics guiding anticoagulant and antiplatelet therapy selection.20.0%
NeurologicalGenetic testing for Alzheimer's, Parkinson's, and rare neurological disorders.15.0%
Infectious DiseasesGenomic surveillance and pathogen sequencing enabling precision antimicrobial strategies.15.0%
OthersIncludes rare diseases, diabetes, and reproductive health applications.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals and Clinics
  • Pharmaceutical Companies
  • Research Institutes
07

Regional Analysis

1

North America

Lead: United States
CAGR: 13.2%Share: 45.0%

Dominant region with advanced healthcare infrastructure, major biotech hubs, and strong R&D funding.

2

Europe

Lead: Germany
CAGR: 11.5%Share: 30.0%

Growing adoption driven by EU genomic initiatives and expanding precision oncology programs.

3

Asia Pacific

Lead: China
CAGR: 16.8%Share: 25.0%

Fastest-growing region with increasing government investment and rapidly expanding genomics infrastructure.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
52.0%
+12.5%
Germany
18.0%
+10.8%
China
30.0%
+19.2%
08

Competitive Landscape

I

Illumina

United States

Leader4.5B

Dominates next-generation sequencing with comprehensive genomic platforms and global installed base.

Global leader in next-generation sequencing technology providing comprehensive genomic analysis platforms.

R

Roche

Switzerland

Challenger68.0B

Major diagnostics and pharma player advancing precision oncology through companion diagnostics and acquisitions.

Integrated diagnostics and pharma giant advancing precision oncology through companion diagnostics and targeted therapies.

N

Novartis

Switzerland

Follower50.5B

Leading CAR-T therapy developer with expanding precision oncology and rare disease portfolios.

Leading CAR-T therapy developer with expanding precision oncology and rare disease treatment portfolios.

09

Recent Developments

25
2025Illumina

Launched NovaSeq X Plus enabling faster and more cost-effective whole-genome sequencing at scale.

24
2024Roche

Expanded precision oncology portfolio through acquisition of Flatiron Health enhancing real-world data capabilities.

10

Regulatory Landscape

FDA Precision Medicine Initiative guidelines for genomic test validation21st Century Cures Act provisions accelerating personalized therapy approvals
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

Prioritize genomics and oncology segments offering strongest growth trajectories and robust therapeutic pipelines.

Operators

Scale AI-driven diagnostic platforms and companion diagnostics to capture rising personalized medicine demand.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.